![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1487, 2005-01, pp. : 9-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Natalizumab benefits QOL in multiple sclerosis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 577, 2009-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Natalizumab knocks out multiple sclerosis
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 555, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Natalizumab knocks out multiple sclerosis
Inpharma, Vol. 1, Iss. 1642, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Natalizumab in multiple sclerosis: proceed with caution?
Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 12, 2006-08 ,pp. :